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Protein kinase B/AKT is a highly connected protein involved in a range of signaling pathways.
Although it is known to regulate several proteins in the apoptotic pathway, its system-level effects
remain poorly understood.We investigated the dynamic interactions between AKT and key apoptotic
proteins and constructed a deterministic ordinary differential equation protein interaction model of
extrinsic apoptosis. Incorporating AKT and its indirect inhibitor, phosphatase and tensin homolog
(PTEN), this was used to generate predictions of system dynamics. Using eigen analysis, we identified
AKT and cytochrome c as the protein species most sensitive to perturbations. Cell death assays in
Type II HCT116 colorectal carcinoma cells revealed a tendency toward Type I cell death behavior in
the XIAP/ background, with cells displaying accelerated TRAIL-induced apoptosis. Finally, AKT inhi-
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Apoptosis is executed by caspases that are activated via intrinsic and extrinsic signaling pathways (Scaffidi
et al., 1998). The intrinsic pathway is initiated by DNA damage, substrate detachment, or growth factor
withdrawal and involves mitochondrial outer membrane permeabilization (MOMP), and the release of
cytochrome c (Fulda and Debatin, 2006). The extrinsic pathway is induced by ligand binding to plasma
membrane receptors of the tumor necrosis factor superfamily, and the downstream molecular cascade
that is triggered is believed to be genetically determined. This pathway can trigger two types of cell death
signaling. First, Type I cells such as lymphocytes undergo mitochondria-independent cell death, relying
solely on a receptor or ligand-instigated caspase cascade (Barnhart et al., 2003; Scaffidi et al., 1998). In
Type II cells, however, amplification through MOMP and cytochrome c release is necessary (Scaffidi
et al., 1998). Understanding how specific cells coordinate apoptotic responses contributes to our appreci-
ation of cell death dynamics in disease.
AKT (protein kinase B) is a promiscuous serine/threonine-specific protein kinase that influences protein
synthesis (Wu, 2013), proliferation (Dong et al., 2015), glucose metabolism (Kornfeld et al., 2013), synaptic
signaling (Liu et al., 2015), autophagy (Heras-Sandoval et al., 2014; Wang et al., 2012), and nuclear factor-kB
signaling (Davoudi et al., 2014). Several studies have also revealed a pivotal role for AKT in apoptosis. AKT
inhibits apoptosis via inhibitory phosphorylation of the pro-apoptotic BCL-2 homology domain 3
(BH3-only) protein BAD (del Peso et al., 1997), triggering a cascade of inhibitory reactions impinging on
pro-apoptotic BAX (AKT C BAD C BCL-2 C BAX; C denoting inhibition). The BCL-2-BAX and BAD-BCL-2 in-
teractions are direct binding associations dependent on their respective BCL-2 homology (BH) domains,
whereas AKT inactivates BAD through phosphorylation at Ser136 leading to AKT sequestration by 14-3-3
proteins (del Peso et al., 1997). AKT also phosphorylates BAX at Ser184, preventing the conformational
changes in BAX needed for oligomerization and pore-forming capabilities during MOMP (Wang et al.,
2010). Downstream of MOMP, AKT phosphorylates procaspase-9 at Ser196, preventing its processing
and activation (Cardone et al., 1998). It also phosphorylates the X-linked inhibitor of apoptosis protein
(XIAP) (Deveraux and Reed, 1999), an E3 enzyme that ubiquitylates caspases 9, 3, and 7, targeting them
for proteasomal degradation. XIAP also regulates its own stability through autoubiquitylation (Nakatani
et al., 2013), a process that is blocked by AKT-mediated Ser87 phosphorylation (Dan et al., 2004). Robust
cell death initiation requires XIAP inhibition via SMAC (secondmitochondria-derived activator of caspases)
that is released during MOMP and binds to the tetrapeptide IAP-binding motif of XIAP (Scott et al., 2005).182 iScience 12, 182–193, February 22, 2019 ª 2019 The Author(s).
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AKT phosphorylates SMAC at Ser67 to increase its binding to XIAP, conferring resistance to apoptosis
(Jeong et al., 2015).
Any systems-level study of the role of AKT during apoptosis must consider PTEN (phosphatase and tensin
homolog). PTEN acts as a positive regulator of apoptosis by antagonizing AKT activation (Baehrecke,
2005); however, it is also downregulated via XIAP-mediated ubiquitylation and degradation (Van Themsche
et al., 2009). In this study, we have constructed a deterministic model of apoptosis incorporating the inter-
actions between AKT, PTEN, and the apoptotic machinery. System dynamics predictions generated using
this model describe how individual protein species as well as the apoptotic system as a whole are affected
in different genetic backgrounds. This model accurately predicts protein dynamics for three of four HCT116
cell lines (wild-type; BAX/; XIAP/), and further investigations uncover the possible mechanisms behind
the dynamics of the fourth (PTEN/). Subsequent laboratory studies show that AKT regulation of
apoptosis is significantly stronger during TRAIL-mediated extrinsic apoptosis than in TRAIL-independent
apoptosis in these cells, and that its effects are more prominent at early points in the apoptotic response.RESULTS
The AKT Apoptosis Model Predicts Protein Dynamics in Different Genetic Backgrounds
Using a simplified model of extrinsic apoptosis as a starting point (Figure 1A), we constructed the AKT
apoptosis model (AKTM) (Figure 1B), a deterministic, single-cell model wherein protein-protein interac-
tions are described by ordinary differential equations and outputs report temporally variable protein
concentrations (Methods). Figures 1C–1F are schematics depicting hypothesized effects of removing the
influential proteins BAX, PTEN, XIAP, and AKT from the system, and the outcomes of AKTM simulations
in these hypothetical scenarios are shown in Figure 2.
Simulated concentrations of active caspase-8 in all scenarios settled at or close to the same steady state
by the end of the simulation. The first condition to reach steady state was XIAP/ (8 h), followed by (1)
AKT/ (10.8 h), (2) wild-type (11 h), (3) PTEN/ (11.3 h), and (4) BAX/, which had not reached steady
state by 16 h (Figure 2B). The active caspase-3 response curves did not settle at the same steady state, but
instead reached peak concentrations at different magnitudes and times—the higher the peak, the earlier it
occurred—in the following order: (1) XIAP/ (7 h), (2) AKT/ (8 h), (3) wild-type (9 h), (4) PTEN/ (10 h),
and (5) BAX/ (12 h) (Figure 2C). Simulated concentrations of active caspase-3 were similar in AKT/ and
PTEN/ simulations, whereas they were 15% higher and 40% lower, respectively, in wild-type and
XIAP/ states (Figure 2C).
Active BAX concentration peaked at 10 h in the wild-type simulation and at 8 h in XIAP/, but required
16 h for PTEN/ (Figure 2D). Peak active BAX concentration was similar in the wild-type and XIAP/ sim-
ulations, but almost 30% lower in the absence of PTEN. The active BAX peak in the AKT/ simulation was
approximately 50% higher than in wild-type, highlighting the AKT-imposed inhibition of BAX. Cytochrome
c (Figure 2G) and SMAC (Figure 2H), the ‘‘products’’ of MOMP, are not released from the mitochondria in
the absence of BAX and therefore never become cytosolic in the BAX/ simulation. Compared with
wild-type, their release was slower in the PTEN/ state, but faster in AKT/ and XIAP/ scenarios.
Cytoplasmic cytochrome c concentration settled at roughly the same steady state in these conditions (Fig-
ure 2G), but cytosolic SMAC concentration began to decay in the wild-type and PTEN/ simulations
(Figure 2H).
In the PTEN/ simulation, XIAP concentration did not begin to decay as quickly as in the other states,
remaining the highest for the first 2–3 h until its decay speed increased (Figure 2J). Henceforth, XIAP con-
centration became greatest in the BAX/ state, eventually fully depleting in all simulations by the 6-h mark
(Figure 2J). The PTEN/ simulation also showed a comparatively large peak in active AKT concentration,
evidence of the modeled AKT inhibition by PTEN (Figure 2K).
The concentration-response curves for the aforementioned proteins are useful for understanding the
underlying mechanisms governing system dynamics, but the overall apoptotic response is reported in
the response curves for cleaved poly(ADP-ribose) polymerase (PARP) (Figure 2M). These presented the
same sigmoid shape in each scenario, the only difference being the timing of the increase phase, which
was initiated after 1 h in XIAP/, 2.6 h in AKT/, 3.2 h in wild-type, 3.8 h in PTEN/, and 5.7 h iniScience 12, 182–193, February 22, 2019 183
Figure 1. The AKT Apoptosis Model Predicts Protein Dynamics in Different Genetic Backgrounds
(A) Extrinsic apoptosis signaling pathway.
(B) The AKT apoptosis model (AKTM). Protein species shown in green are those for which double knockout HCT116 cell lines are used in this study. TRAIL,
TNF-related apoptosis-inducing ligand; C8, active caspase-8; BAX, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma 2; SMAC, second mitochondria-
derived activator of caspases; CytoC, cytochrome c; XIAP, X-linked inhibitor of apoptosis protein; AKT, protein kinase B; PTEN, phosphatase and tensin
homolog; C3, active caspase-3.
(C) Predicting the effects of BAX removal on the AKTM. Green lines signify a predicted increased response, and red lines signify a reduced response.
(D) Predicted effects of XIAP removal on the AKTM.
(E) Predicted effects of PTEN removal on the AKTM.
(F) Predicted effects of AKT removal on the AKTM.BAX/. In all simulations, the increase phase lasted for 4.5 h, such that steady state was reached at 5.3 h
in XIAP/, 7.1 h in AKT/, 7.7 h in wild-type, 8.3 h in PTEN/, and 10.2 h in BAX/ (Figure 2M).Eigen Analysis Reveals Perturbation Sensitivity of AKT and Cytochrome c
Eigen analysis was performed on the wild-type variant of the model, and of the 41 eigenvalues computed
only three were positive at any point during the simulation. Positive eigenvalues indicate instability, and
their corresponding eigenvectors represent the protein species whose relative concentrations have
changed (Methods). The three positive eigenvalues are shown in Figures 3A–3C, along with their corre-
sponding most sensitive temporally variable protein species in Figures 3D–3F.
ActiveAKTwas identifiedas theprotein speciesmost sensitive toperturbations (Figure3D, i), as calculated from
eigenvalue 1 (Figure 3A) from the start of the simulation to a fewminutes after the 3-h mark, the point at which184 iScience 12, 182–193, February 22, 2019
Figure 2. AKTM Simulation Results
(A–H and J–M) Simulated concentrations of the following protein species in the HCT116 wild-type, BAX/, PTEN/,
XIAP/, and AKT/ cell lines for a 16-h period following exposure to TRAIL and cycloheximide: (A) TRAIL, (B) active
caspase-8, (C) active caspase-3, (D) active BAX, (E) Bcl-2, (F) mitochondrial pore, (G) cytochrome c, (H) SMAC, (J) XIAP, (K)
active AKT, (L) PTEN, and (M) cleaved PARP.AKTconcentration peaked (Figure 2K). Subsequently, PARPgovernedmodel dynamics until 4.4 h (Figure 3D, ii),
when cleaved PARP concentration reached a steady increase (Figure 2M). Cytosolic cytochrome c then became
dominant, corresponding to themiddle of its exponential phase in the simulation (Figure 2G). Finally,mitochon-
drial cytochrome c assumed responsibility at the 6-h mark (Figure 3D, iii), when the rate of increase in cytosolic
cytochromecbegan tobecomestable (Figure2G).Thiswasalso thepoint atwhich the rateof increase incleaved
PARP concentration began to slow (Figure 2M). Mitochondrial cytochrome cmaintained dominance of eigen-
value 1 dynamics until 8 h (Figure 3D, iv), when complete cell death had been reached (signified by the concen-
tration of cleaved PARP reaching its maximum steady state [Figure 2M]).
Eigenvalue 2 only became positive after 3.3 h when cleaved PARP was dominating its dynamics (Figure 3E,
i). This continued until mitochondrial cytochrome c took over at 4.4 h (Figure 3E, ii) once the increase in
cleaved PARP had become steady (Figure 2M) and the increase in the rate of release of mitochondrial
cytochrome c was in its exponential phase (Figure 2G). The eigenvalue became negative at 5.1 h and could
therefore not be regarded as unstable after this period. It did, however, become positive again for 0.2 h
immediately before the 8-h mark, at which point cytosolic cytochrome c governed its dynamics (Figure 3E,
iii). Taken together with eigenvalue 1, the period from 4.4–8 h is dominated by cytochrome c release dy-
namics as it is largely the mitochondrial and cytosolic cytochrome c species that control the dynamics of
eigenvalues 1 and 2 during this period.
Eigenvalue 3 also only became positive after 3.3 h, at which point cytosolic cytochrome c was dominating
its dynamics (Figure 3F, i). At the 4.4-h mark, cleaved PARP briefly (2 min) took over (Figure 3F, ii),
before PARP assumed greater responsibility for eigenvalue 3 dynamics until 5.1 h, while it was still positiveiScience 12, 182–193, February 22, 2019 185
Figure 3. Eigen Analysis Reveals Perturbation Sensitivity of AKT and Cytochrome c
(A–C) Eigen analysis of the three positive eigenvalues present in the wild-type system: (A) eigenvalue 1 (most positive),
(B) eigenvalue 2, and (C) eigenvalue 3 (least positive).
(D) The temporally variable protein species most responsible for eigenvalue 1 dynamics: (i) active AKT, (ii) PARP, (iii)
cytosolic cytochrome c, and (iv) mitochondrial cytochrome c.
(E) Eigenvalue 2 dynamics: (i) cleaved PARP, (ii) mitochondrial cytochrome c, and (iii) cytosolic cytochrome c.
(F) Eigenvalue 3 dynamics: (i) cytosolic cytochrome c, (ii) cleaved PARP, and (iii) PARP.(Figures 3F, iii). The eigenvalue was then negative for the remainder of the simulation, and there are no
other positive eigenvalues to identify. In addition to the sensitivity to perturbations of cytochrome c
revealed by eigenvalues 1 and 2, eigenvalue 3 highlights the sensitivity of PARP, but only until MOMP
transition initiated (i.e., the point of no return).
Cell Death Assays Validate AKTM Predictions
We next tested the accuracy of our model in vitro using BAX/, PTEN/, and XIAP/ HCT116 cell lines.
Figure 4 shows cell death assay results represented as percentage cell death for control/untreated (Figures
4A), 2.5 mg/mL cycloheximide (CHX)-treated (Figure 4B), and 50 ng/mL TRAIL + 2.5 mg/mL CHX-treated
cells (Figure 4C). As expected, TRAIL + CHX (Figure 4C) caused the highest cell death: by the end of
the 16-h imaging period all cells were dead in the PTEN/ and XIAP/ lines, whereas cell death in the
BAX/ (83.4%G 2.8%) and wild-type (95.1%G 2.1%) lines was marginally delayed. Time taken to achieve
50% cell death was also recorded for these treatments (Figure 4D), demonstrating significantly delayed
apoptosis in the BAX/line and significantly advanced apoptosis in the XIAP/ line. There was no signif-
icant difference between the PTEN/ and wild-type lines.
The most obvious (althoughminor) discrepancy between simulation and experimental data was seen in the
PTEN/ line. Here, the model predicted a slight delay in the onset of apoptosis, whereas the data re-
ported an advanced apoptotic onset, despite similar time to 50% cell death recordings (Figure 4D). This
may be due to inaccurate model parameterization; however, we chose to investigate this further through
protein quantification.
Absence of BAX Expression in PTEN/ HCT116 Cells
Immunoblotting was performed on the wild-type, BAX/, PTEN/, and XIAP/ HCT116 cell lines using
antibodies against AKT, p-AKT Ser473, PTEN, XIAP, and BAX (tubulin was used as a loading control) (Fig-
ure 5A). AKT levels in the three knockout cell lines were similar to those in wild-type (Figure 5B).
The same was true for p-AKT Ser473 in the BAX/ and XIAP/ lines, but p-AKT Ser473 was significantly
higher in the PTEN/ line compared with the wild-type (p < 0.05; Figure 5C), as would be expected
with no PTEN-imposed AKT inhibition. The PTEN level in the BAX/ line did not differ significantly
from wild-type, but it was significantly higher in the XIAP/ line (p < 0.05; Figure 5D), consistent with its
role in stimulating PTEN degradation (Van Themsche et al., 2009). XIAP levels did not differ between the
BAX/ and PTEN/ lines (Figure 5E). Surprisingly, however, BAX was not detected in the PTEN/ line
(Figure 5F). To further examine this unexpected finding, we first carried out qRT-PCR to measure BAX186 iScience 12, 182–193, February 22, 2019
Figure 4. Cell Death Assays Validate AKTM Predictions
(A) Percentage cell death in untreated (control) HCT116 cells.
(B) Percentage cell death in HCT116 cells treated with 2.5 mg/mL cycloheximide.
(C) Percentage cell death in HCT116 cells treated with 50 ng/mL TRAIL and 2.5 mg/mL cycloheximide.
(D) Time to 50% cell death in HCT116 cells treated with 50 ng/mL TRAIL and 2.5 mg/mL cycloheximide. BAX/ cells
reached 50% cell death significantly later than in wild-type (p < 0.05), PTEN/ cells did not significantly differ from wild-
type, and XIAP/ cells reached 50% cell death significantly earlier (p < 0.01).
Data in (A–D) represent meansG SD from three independent biological repeats. SDs are represented by shaded areas in
(A–C) and by error bars in (D). * in (D) indicates a mean significantly different from that of the wild-type cell line with p%
0.05 (Welch two-sample t test); ** signifies p% 0.01. Detailed statistical results are displayed in Table S5.mRNA levels in the PTEN/ line. BAXmRNAwas detected at the same level in wild-type and PTEN/ cells
(Figure 5H), arguing that the absence of BAX protein in PTEN/ cells was not due to impaired transcrip-
tion. Treatment with inhibitors of proteasomal (MG132) and/or lysosomal (bafilomycin A1) degradation did
not restore BAX protein levels in PTEN/ cells, suggesting that the absence of BAX was not caused by
rapid protein degradation (data not shown). Furthermore, immunoprecipitation suggested the absence
of any interaction between PTEN and BAX in wild-type HCT116 cells (Figure 5J), arguing that PTEN
does not help to stabilize BAX under normal conditions. This was further corroborated by small interfering
RNA (siRNA)-mediated silencing of PTEN in wild-type HCT116 cells, as suppression of PTEN expression did
not lead to reduced levels of BAX (Figure 5K).
In the light of the observed absence of BAX in the PTEN/ HCT116 line, it should subsequently be
considered as both PTEN and BAX deficient. Additional modeling was therefore performed to simulate
the lack of BAX in the PTEN/ background (BAX/PTEN/; Figure S1). Rather than generating a
cleaved PARP concentration-response curve that matched the PTEN/ scenario, this model reported
a response curve that was almost identical to BAX/ (Figure S1A). The BAX/PTEN/ response curves
for the majority of other protein species also matched BAX/ (data not shown), with the following ex-
ceptions: the active AKT curve increased in line with PTEN/ but instead of peaking and falling to a
lower steady state, it continued rising to an approximately 3-fold higher steady state (Figure S1B);
the XIAP curve began following the trajectory of PTEN/, but converged with BAX/ at the 6-h
mark (Figure S1C).AKT Regulates Early TRAIL-Induced Apoptosis
To complement the modeling data, we next focused on AKT and its temporally variable effects on
apoptosis using an IncuCyte imaging system. Wild-type and homozygous knockout HCT116 cells were
treated with an AKT1/2 inhibitor (AKTi), in combination with TRAIL and/or CHX (Figure 6: panels A–F
show cell death over a 16-h time course; panels G–Q show time-slice data at 4, 6, and 8 h). ImmunoblottingiScience 12, 182–193, February 22, 2019 187
Figure 5. Absence of BAX Expression in PTEN/ HCT116 Cells
(A–G) (A) Immunoblotting via western blot of wild-type, BAX/, PTEN/, and XIAP/ HCT116 cell lines for the following proteins: AKT, p-AKT (Ser473),
PTEN, XIAP, BAX, and a-tubulin as a loading control. Densitometry quantitation of (B) AKT, (C) p-AKT Ser473, (D) PTEN, (E) XIAP, (F) BAX, and (G) tubulin.
(H) qRT-PCR of BAX mRNA levels in wild-type, PTEN/, and BAX/ cells.
(J) Immunoblot of immunoprecipitated endogenous BAX and PTEN from wild-type HCT116 cells; FLAG antibody used as a negative control, and 5% of
protein lysate used as control for protein expression.
(K) siRNA-mediated silencing of PTEN in wild-type HCT116 cells.
Data in (B–G) represent normalized means (relative to wild-type = 1) from three independent biological repeats G SD. * indicates a mean significantly
different from that of the wild-type cell line with p% 0.05 (Welch two-sample t test); *** signifies p% 0.001. Detailed statistical results are displayed in
Table S5.
See also Figure S1.provided evidence for increased AKT activity following TRAIL treatment, as measured by increased p-AKT
Ser473 levels, and demonstrated that the AKTi was effective (Figure S2).
Basal cell death rates were highest in the XIAP/ line in the absence or presence of AKTi, and lowest in the
BAX/ line (Figures 6A, 6D, 6G, 6K, and 6N). Variation from wild-type was recorded for the XIAP/ line in
the absence of AKTi (significantly higher at 4 and 8 h in the absence of AKTi; Figures 6G and 6N), and for
BAX/ (significantly lower at 4 and 6 h with AKTi; Figures 6G and 6K). Inclusion of CHX (Figures 6B, 6E, 6H,
6L, and 6P) caused a 4- to 5-fold increase in basal cell death kinetics across all cell lines (relative to untreated188 iScience 12, 182–193, February 22, 2019
Figure 6. AKT Regulates Early TRAIL-Induced Apoptosis
(A–F) IncuCyte-derived percentage cell death in wild-type, BAX/, PTEN/, and XIAP/ HCT116 cell lines over a 16-h
time course. +AKTi treatments contained 27.6 mg/mL AKT1/2 kinase inhibitor; +TRAIL treatments, 50 ng/mL TRAIL;
and +CHX treatments, 2.5mg/mL cycloheximide. Data in (A–F) represent meansG SD from three independent biological
repeats taken at 30-min intervals. SDs are represented by shaded areas. For clarity, y axes (% cell death) are not all scaled
to 100%. Treatments: (A) -AKTi -TRAIL –CHX, (B) -AKTi -TRAIL + CHX, (C) -AKTi + TRAIL + CHX, (D) +AKTi -TRAIL –CHX,
(E) +AKTi -TRAIL + CHX, and (F) +AKTi + TRAIL + CHX.
(G–Q) Time slices of A–F at 4- (G–J), 6- (K–M), and 8-h (N–Q) treatment, showing the effects of AKT inhibition across all
TRAIL/CHX treatments. SDs here are represented by error bars. Asterisks above individual bars indicate values
significantly different from wild-type within each treatment, whereas asterisks above lines spanning treatments indicate
values from the same cell line that differ significantly between treatments. *p % 0.05 (Welch two-sample t test); **p%
0.01. Detailed statistical results are displayed in Table S5.
See also Figures S2 and S3.
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cells; compare Figures 6A and 6D with Figures 6B and 6E). The XIAP/ line again displayed the most rapid
cell death kinetics, and the BAX/ line the slowest, although in the absence of AKTi, XIAP/ cell death was
significantly greater than wild-type only at the 8-h mark (Figure 6P). In the presence of CHX and AKTi, cell
death was significantly higher in XIAP/ than wild-type cells (6 h; Figure 6L), and lower in BAX/ cells
(6 and 8 h; Figures 6L and 6P). AKT inhibition in CHX-treated cells altered cell death responses only in
the XIAP/ line at the 6-h mark (significantly higher; Figure 6L).
Treatments with both CHX and TRAIL (Figures 6C and 6F) generated considerably higher levels of cell
death in all cell lines, as anticipated. Cell death levels differed significantly from wild-type across all time
points in both the BAX/ (lower in the absence and presence of AKTi) and XIAP/ (higher in the absence
of AKTi). In the XIAP/ line in the presence of AKTi, cell death was significantly higher than wild-type only
at the 6-h point as cell death approached 100% for both conditions (Figure 6M). Of note, AKT inhibition
increased cell death rates most effectively in TRAIL/CHX-treated cells, and this was especially apparent
at the 4- and 6-h points (Figures 6J and 6M).
An important finding from these cell death experiments was that cell death in the PTEN/ line did not
differ significantly from that of wild-type under any condition (despite these cells apparently lacking
BAX; Figures 5A and 5F). Furthermore, there were no instances wherein AKT inhibition significantly altered
cell death rates in the PTEN/ line, arguing that PTEN has a negligible influence over cell death dynamics
during TRAIL-induced apoptosis. In support of this, cell death analysis by caspase activity in cells trans-
fected with GFP, wild-type PTEN, or catalytically inactive C124S PTEN (Myers et al., 1997) suggested
that overexpression of PTEN in active or inactive forms did not alter apoptosis kinetics in cells treated
with TRAIL (Figure S3).DISCUSSION
Mathematical modeling can be used to generate predictions of how complex systems, such as apoptosis,
behave under different conditions. Here, we have constructed a simplified model to describe the dynamics
of the extrinsic apoptotic pathway with sufficient accuracy to provide a framework to test predictions in the
laboratory. Using cleaved PARP concentration as an indicator of apoptosis (Figure 2M), themodel behaved
as predicted for both the removal of BAX and XIAP, with a delayed and hastened onset of apoptosis,
respectively. These predictions were based on the same BAX/ HCT116 cell line used in this study having
previously been used to demonstrate a delayed—albeit not abolished—apoptotic response (Zhang et al.,
2000; Wang and Youle, 2012), and the XIAP/ HCT116 cell line having demonstrated the opposite
(Cummins et al., 2004). The model did not, however, simulate the large expected delay in onset for the
removal of PTEN. This expectation was based on the known role of PTEN as a tumor suppressor (Li
et al., 1997; Lee et al., 2004). To our knowledge, the PTEN/ HCT116 cell line has not previously been
used for the purpose of this study.
Using TRAIL as a death-inducing ligand, cell death kinetics very closely resembled the sigmoid-shaped
curves of cleaved PARP concentration from the simulation (Figure 2M). More specifically, the BAX/
and XIAP/ cell lines responded as predicted by the model, with a later onset and earlier onset of cell
death, respectively. HCT116 cells are known to be Type II cells (Bentele et al., 2004; Aldridge et al.,
2011; Gillissen et al., 2013; Huang et al., 2016), and several studies have suggested that whether a cell
follows this behavior or that of Type I depends largely on the relative concentrations of various key
apoptotic proteins (Aldridge et al., 2011; Gillissen et al., 2013; Scaffidi et al., 1998). In Type II cells,
caspase-8 does not activate sufficient caspase-3 to trigger apoptosis, largely due to the overwhelming
concentration of XIAP, meaning that amplification through BAX-mediated MOMP is needed (Scaffidi
et al., 1998). Aldridge et al. (2011) showed that the defining factor for Type II cells is a high XIAP to
caspase-3 concentration ratio, but that there might also be other factors involved such as the efficiency
of caspase-8-mediated BID cleavage (O¨zo¨ren and El-Deiry, 2002). Some studies have also shown that
within a single cell line, genetic or pharmacological manipulation affecting the expression of certain
proteins—such as XIAP or BAX/BAK—can cause Type II cells to adapt to Type I behavior, and that the
extent to which this occurs is concentration dependent rather than being a binary switch between the
two (Aldridge et al., 2011; Gillissen et al., 2013).
In the present study, the removal of BAX from the system slowed down the onset of apoptosis, but did not
prevent it entirely. This may be in part due to the cells adapting tomore of a Type I behavior, and it may also190 iScience 12, 182–193, February 22, 2019
be partly because these cells were only BAX/ and not double BAX/BAK/ (required to fully disable the
mitochondrial apoptotic pathway; Zhang et al., 2000). In the absence of XIAP, the very rapid apoptotic
response suggests that these cells are reverting to Type I. Indeed, Gillissen et al. (2013) showed that
silencing XIAP led to mitochondria-independent cell death (Type I) in BAX/BAK/ HCT116 cells.
The PTEN/ line, however, did not match model predictions, having an earlier onset similar to the XIAP/
line. This is counterintuitive, as PTEN is an indirect inhibitor of AKT, which itself is an inhibitor of apoptosis.
Strikingly, BAX protein was found to be missing in the PTEN/ line (Figures 5A and 5F), although surpris-
ingly its transcript was present at control levels. Further analysis of BAX stability in PTEN/ cells treated
with proteasomal and/or lysosomal inhibitors suggested that the absence of BAX protein was not due
to enhanced turnover. In addition, siRNA silencing of PTEN expression in wild-type HCT116 cells was
not associated with a marked reduction in BAX, arguing against direct causality between PTEN expression
and BAX protein levels. Taken together, our data imply that some other form of post-transcriptional regu-
lation of BAX in these cells is resulting in its absence.
According to both the model and the experimental data, the absence of BAX should cause a substan-
tial delay in apoptotic onset, yet this was not observed in the PTEN/ line. Additional modeling of a
hypothetical BAX/PTEN/ cell line produced a cleaved PARP response curve almost identical to that
of the BAX/ line (Figure S1), showing that the current model cannot fully explain this anomaly. This
additional modeling does, however, suggest that PTEN has some influence on XIAP early in the
apoptotic response and on AKT throughout, but this is still not sufficient to significantly affect the
overall apoptotic dynamics. In the model, the BAX/PTEN/ response curve for cleaved PARP behaves
as BAX/, suggesting a much stronger influence of BAX than PTEN on the system. As the percentage
of cell death in the PTEN/ cell line did not significantly differ from that in the wild-type, the absence
of BAX in this background is less influential. This could imply XIAP-imposed compensatory regulation
on the PTEN/ system, because free XIAP levels are likely to be higher in the absence of one of its
substrates (PTEN), as the model suggests (Figure 2J). This was not, however, reflected in the total
XIAP levels (Figure 5E). Overall, this is indicative of the noise that can often be introduced when at-
tempting to characterize a nonlinear complex system.
Eigenanalysis of the wild-type model revealed AKT, cytochrome c, and PARP as the protein species
most sensitive to perturbations. The mitochondrial release of cytochrome c marks the point of no
return in a dying cell and PARP cleavage is the ultimate readout of the model, whereas AKT acts
on the system before MOMP and was therefore a good candidate to manipulate experimentally.
Investigating AKT dynamics also proved interesting from a modeling perspective because the
removal of AKT predicted a large increase in active BAX concentration (Figure 2D) and advanced cy-
tochrome c mitochondrial release similar to the XIAP/ simulation (Figure 2G), yet minor advance-
ment in the cleavage of PARP (Figure 2M).
In subsequent live-cell imaging experiments, AKT inhibition advanced cell death to the greatest extent
during early TRAIL-dependent apoptosis, but did so in all cell lines except PTEN/ (Figure 6). In addition,
PTEN/ cells did not differ significantly from wild-type under any treatment, despite their lax of BAX
protein. In addition to the possible XIAP-imposed compensatory effect proposed earlier, the inherent
interconnectivity of AKT in numerous cellular signaling pathways might explain this unexpected finding.
It is possible that one or more of the myriad interactions between AKT and other signaling pathways are
causing compensatory effects in the absence of PTEN, resulting in variability in the very nature of the
apoptotic regulatory mechanisms of AKT. Pursuing an answer to this question represents a prime example
of how the numerous potential protein interactions inherent to the study of complex systems require an
interdisciplinary approach.Limitations of the Study
An obvious limitation of any experimental work that uses cell lines in culture is whether a given cell type is
representative of its tissue of origin or cells in general. This is particularly true for transformed cells derived
from human tumors, for example, that accumulate specific mutations likely to alter their cell growth and/or
cell death kinetics. Although in this case our computer-based model has been able to predict with some
accuracy the cell death kinetics of a cell line in culture (in this case, HCT116 cells)—arguing that there is
a reasonable level of functional plasticity in the mode—it is unlikely that such a predictive system wouldiScience 12, 182–193, February 22, 2019 191
be applicable to all cells. There is direct evidence for this in our comparisons of predictive and actual cell
death kinetics in the PTEN/ cell line. With respect to this cell line, as we were unable to identify the pre-
cise mechanism behind the absence of BAX protein in PTEN/ cells, we must also consider the use of this
cell line as a limitation of the study.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
DATA AND SOFTWARE AVAILIBILITY
Raw data for the cell death assays (Figure 4), Western blot quantification (Figure 5), and AKT inhibition ex-
periments (Figure 6) are available online via a Mendeley Data repository with DOI links as follows: Cell
death assays (Figure 4): https://doi.org/10.17632/hvwswmgg7p.1 Western blot quantification (Figure 5):
https://doi.org/10.17632/x8v9937psj.1 AKT inhibition experiments (Figure 6): https://doi.org/10.17632/
74pf4wwdd4.1.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Transparent Methods, three figures, five tables, and one data file and
can be found with this article online at https://doi.org/10.1016/j.isci.2019.01.015.
ACKNOWLEDGMENTS
We thank Bree Aldridge and John Albeck for their previous work and useful modeling discussions, Alex-
ander Greenhough and Bert Vogelstein for the provision of cell lines, Emma Vincent for advice and re-
agents, Tilo Burghardt for advice on image analysis, and members of the Lane laboratory for comments
on experimental development. In particular, we would like to thank Dr. Lucy Crompton for assistance
with the qRT-PCR and caspase assays. This work was supported primarily by the EPSRC (EP/I013717/1),
with much of the analysis and writing generously supported by the Wellcome Trust Institutional Strategic
Support Award (204909/Z/16/Z).
AUTHOR CONTRIBUTIONS
M.W.A. and R.S. developed the model; M.W.A., J.J.M., and J.D.L. designed the experiments and collected
data; and M.W.A. developed image analysis software and ran model simulations and analyses. All authors
wrote the paper.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: July 4, 2018
Revised: December 13, 2018
Accepted: January 8, 2019
Published: February 22, 2019REFERENCES
Aldridge, B.B., Gaudet, S., Lauffenburger, D.A.,
and Sorger, P.K. (2011). Lyapunov exponents and
phase diagrams reveal multi-factorial control over
TRAIL-induced apoptosis. Mol. Syst. Biol. 7, 553.
Baehrecke, E.H. (2005). Autophagy: dual roles in
life and death? Nat. Rev. Mol. Cell Biol. 6,
505–510.
Barnhart, B.C., Alappat, E.C., and Peter, M.E.
(2003). The CD95 type I/type II model. In Seminars
in Immunology, Vol. 15, D.R. Green, ed., Seminars
in Immunology (Academic Press), pp. 185–193.
Bentele, M., Lavrik, I., Ulrich, M., Sto¨sser, S.,
Heermann, D.W., Kalthoff, H., Krammer, P.H., and
Eils, R. (2004). Mathematical modeling reveals192 iScience 12, 182–193, February 22, 2019threshold mechanism in CD95-induced
apoptosis. J. Cell Biol. 166, 839–851.
Cardone, M.H., Roy, N., Stennicke, H.R.,
Salvesen, G.S., Franke, T.F., Stanbridge, E.,
Frisch, S., and Reed, J.C. (1998). Regulation of cell
death protease caspase-9 by phosphorylation.
Science 282, 1318–1321.
Cummins, J.M., Kohli, M., Rago, C., Kinzler, K.W.,
Vogelstein, B., and Bunz, F. (2004). X-linked
inhibitor of apoptosis protein (XIAP) is a
nonredundant modulator of tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL)-
mediated apoptosis in human cancer cells.
Cancer Res. 64, 3006–3008.Dan, H.C., Sun, M., Kaneko, S., Feldman, R.I.,
Nicosia, S.V., Wang, H.G., Tsang, B.K., and
Cheng, J.Q. (2004). Akt phosphorylation and
stabilization of X-linked inhibitor of apoptosis
protein (XIAP). J. Biol. Chem. 279, 5405–5412.
Davoudi, Z., Akbarzadeh, A., Rahmatiyamchi, M.,
Movassaghpour, A.A., Alipour, M., Nejati-Koshki,
K., Sadeghi, Z., Dariushnejad, H., and Zarghami,
N. (2014). Molecular target therapy of AKT and
NF-kB signaling pathways and multidrug
resistance by specific cell penetrating inhibitor
peptides in HL-60 cells. Asian Pac. J. Cancer Prev.
15, 4353–4358.
del Peso, L., Gonza´lez-Garcıa, M., Page, C.,
Herrera, R., and Nun˜ez, G. (1997).
Interleukin-3- induced phosphorylation of
BAD through the protein kinase Akt. Science
278, 687–689.
Deveraux, Q.L., and Reed, J.C. (1999). IAP family
proteins—suppressors of apoptosis. Genes Dev.
13, 239–252.
Dong, Y., Liang, G., Yuan, B., Yang, C., Gao, R.,
and Zhou, X. (2015). MALAT1 promotes the
proliferation and metastasis of osteosarcoma
cells by activating the PI3K/Akt pathway. Tumor
Biol. 36, 1477–1486.
Fulda, S., and Debatin, K.M. (2006). Extrinsic
versus intrinsic apoptosis pathways in anticancer
chemotherapy. Oncogene 25, 4798–4811.
Gillissen, B., Richter, A., Overkamp, T., Essmann,
F., Hemmati, P.G., Preissner, R., Belka, C., and
Daniel, P.T. (2013). Targeted therapy of the XIAP/
proteasome pathway overcomes TRAIL-
resistance in carcinoma by switching apoptosis
signaling to a Bax/Bak-independent ‘type I’
mode. Cell Death Dis. 4, e643.
Heras-Sandoval, D., Pe´rez-Rojas, J.M.,
Herna´ndez-Damia´n, J., and Pedraza-Chaverri, J.
(2014). The role of PI3K/AKT/mTOR pathway in
the modulation of autophagy and the clearance
of protein aggregates in neurodegeneration.
Cell. Signal. 26, 2694–2701.
Huang, K., Zhang, J., O’Neill, K.L.,
Gurumurthy, C.B., Quadros, R.M., Tu, Y., and
Luo, X. (2016). Cleavage by caspase 8 and
mitochondrial membrane association activate
the BH3-only protein bid during TRAIL-
induced apoptosis. J. Biol. Chem. 291,
11843–11851.
Jeong, C.H., Chun, K.S., Kundu, J., and Park, B.
(2015). Phosphorylation of Smac by Akt promotes
the caspase-3 activation during etoposide-induced apoptosis in HeLa cells. Mol. Carcinog.
54, 83–92.
Kornfeld, J.W., Baitzel, C., Ko¨nner, A.C., Nicholls,
H.T., Vogt, M.C., Herrmanns, K., Scheja, L.,
Haumaitre, C., Wolf, A.M., Knippschild, U., and
Seibler, J. (2013). Obesity-induced
overexpression of miR-802 impairs glucose
metabolism through silencing of Hnf1b. Nature
494, 111–115.
Lee, C., Kim, J.S., and Waldman, T. (2004). PTEN
gene targeting reveals a radiation-induced size
checkpoint in human cancer cells. Cancer Res. 64,
6906–6914.
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S.,
Wang, S.I., Puc, J., Miliaresis, C., Rodgers, L., and
Bigner, S.H. (1997). PTEN, a putative protein
tyrosine phosphatase gene mutated in human
brain, breast, and prostate cancer. Science 275,
1943–1947.
Liu, D., Wei, N., Man, H.Y., Lu, Y., Zhu, L.Q., and
Wang, J.Z. (2015). The MT2 receptor stimulates
axonogenesis and enhances synaptic
transmission by activating Akt signaling. Cell
Death Differ. 22, 583–596.
Myers, M.P., Stolarov, J.P., Eng, C., Li, J., Wang,
S.I., Wigler, M.H., Parsons, R., and Tonks, N.K.
(1997). P-TEN, the tumor suppressor from human
chromosome 10q23, is a dual-specificity
phosphatase. Proc. Natl. Acad. Sci. U S A 94,
9052–9057.
Nakatani, Y., Kleffmann, T., Linke, K., Condon,
S.M., Hinds, M.G., and Day, C.L. (2013).
Regulation of ubiquitin transfer by XIAP, a dimeric
RING E3 ligase. Biochem. J. 450, 629–638.
O¨zo¨ren, N., and El-Deiry, W.S. (2002). Defining
characteristics of Types I and II apoptotic cells in
response to TRAIL. Neoplasia 4, 551–557.Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C.,
Li, F., Tomaselli, K.J., Debatin, K.M., Krammer,
P.H., and Peter, M.E. (1998). Two CD95
(APO-1/Fas) signaling pathways. EMBO J. 17,
1675–1687.
Scott, F.L., Denault, J.B., Riedl, S.J., Shin, H.,
Renatus, M., and Salvesen, G.S. (2005). XIAP
inhibits caspase-3 and-7 using two binding sites:
evolutionarily conserved mechanism of IAPs.
EMBO J. 24, 645–655.
Van Themsche, C., Leblanc, V., Parent, S., and
Asselin, E. (2009). X-linked inhibitor of apoptosis
protein (XIAP) regulates PTEN ubiquitination,
content, and compartmentalization. J. Biol.
Chem. 284, 20462–20466.
Wang, C., and Youle, R.J. (2012). Predominant
requirement of Bax for apoptosis in HCT116 cells
is determined by Mcl-1’s inhibitory effect on Bak.
Oncogene 31, 3177.
Wang, Q., Sun, S.Y., Khuri, F., Curran, W.J., and
Deng, X. (2010). Mono-or double-site
phosphorylation distinctly regulates the
proapoptotic function of Bax. PLoS One 5,
e13393.
Wang, R.C., Wei, Y., An, Z., Zou, Z., Xiao, G.,
Bhagat, G., White, M., Reichelt, J., and Levine,
B. (2012). Akt-mediated regulation
of autophagy and tumorigenesis through
Beclin 1 phosphorylation. Science 338,
956–959.
Wu, G. (2013). Amino Acids: Biochemistry and
Nutrition (CRC Press).
Zhang, L., Yu, J., Park, B.H., Kinzler, K.W., and
Vogelstein, B. (2000). Role of BAX in the apoptotic
response to anticancer agents. Science 290,
989–992.iScience 12, 182–193, February 22, 2019 193
ISCI, Volume 12Supplemental InformationMathematical Modeling Highlights
the Complex Role of AKT in TRAIL-Induced
Apoptosis of Colorectal Carcinoma Cells
Matthew W. Anderson, Joanna J. Moss, Robert Szalai, and Jon D. Lane
Figure S1. Comparisons of protein concentration dynamics as predicted by the AKTM. 
Related to Figure 5. 
Response curves in the wild-type, BAX-/-, PTEN-/-, XIAP-/-, and BAX/PTEN-/- modelled cell lines for 
the following proteins: (A) cleaved PARP; (B) active AKT; (C) XIAP. 
 
 
 
 
Figure S2. TRAIL treatment causes increased AKT activity. Related to Figure 6. 
Immunoblot of wild-type HCT116 cells treated with CHX in the absence or presence of TRAIL, 
with or without AKTi (as above). Lysates were blotted for total and p-AKT Ser473. 
 
 
Figure S3. PTEN does not alter apoptosis in cells treated with TRAIL. Related to Figure 6. 
Fluorometric caspase assays analyzing cell death in wild-type HCT116 cells transfected with 
IRES-GFP, PTEN-IRES-GFP or C124S catalytic mutant PTEN-IRES-GFP.
 
 
Table S1. List of Protein Species in the AKTM. Related to Figures 1 and 2. 
Protein ID corresponds to the xpi (protein concentration differential), xi (protein concentration), si 
(synthesis rate constant), and ri (degradation rate constant) subscripts, i, in Table S4. 
 
Protein 
ID (i) 
Protein Species Description 
1 TRAIL TNF-related apoptosis-inducing ligand 
2 pC8 Procaspase-8/10; inactive caspase-8/10 
3 C8* Cleavage-activated Caspase-8/10 
4 pC3 Procaspase-3/7; inactive caspase-3/7 
5 C3* Cleavage-activated Caspase-3/7 
6 BAX Bcl-2-associated X protein (inactive, cytosolic) 
7 BAX* BAX (active, cytosolic) 
8 Mito Mitochondrial pores; unoccupied BAXm binding sites 
9 Mito* BAXm-bound mitochondrial pores (active) 
10 Cytocm Cytochrome c (mitochondrial) 
11 Cytocc Cytochrome c (cytosolic) 
12 SMACm Second mitochondria-derived activator of caspases (mitochondrial) 
13 SMACc SMAC (cytosolic) 
14 PTEN Phosphatase and tensin homolog 
15 AKT Protein kinase B / AKT 
16 AKT* AKT (active) 
17 AKT:Cytocc Reaction intermediary 
18 Bcl-2 B-cell lymphoma 2 
19 Bcl-2:BAXm Reaction intermediary 
20 XIAP X-linked inhibitor of apoptosis protein 
21 SMACc:XIAP Reaction intermediary 
22 BAXm BAX (active, mitochondrial) 
23 AKT:BAX* Reaction intermediary 
24 PARP Poly(ADP-ribose) polymerase 
25 cPARP Caspase-3/7-cleaved PARP 
26 TRAIL:pC8 Reaction intermediary 
27 C8*:pC3 Reaction intermediary 
28 C3*:pC8 Reaction intermediary 
29 C8*:BAX Reaction intermediary 
30 Mito:Cytocm Reaction intermediary 
31 Mito:SMACm Reaction intermediary 
32 Cytocc:pC3 Reaction intermediary 
33 PTEN:AKT* Reaction intermediary 
34 SMACc:XIAP:AKT*  Reaction intermediary 
35 C3*:PARP Reaction intermediary 
36 AKT*:XIAP Reaction intermediary 
37 C3*:XIAP Reaction intermediary 
38 C3Ub Ubiquitinated caspase-3/7 
39 PTEN:XIAP Reaction intermediary 
40 PTENUb Ubiquitinated PTEN 
41 XIAP:Cytocc Reaction intermediary 
 
  
Table S2. Initial Conditions and Synthesis/Degradation Rates. Related to Figures 1 and 2. 
Protein 
ID (i) 
Protein Species Initial Condition 
(molecules/cell) 
Synthesis Rate 
(si , molecules s-1) 
Degradation Rate 
(ri , s-1) 
1 TRAIL 1,000 0 5.79 x 10-6 
2 pC8 3,500 2.03 x 10-2 5.79 x 10-6 
3 C8* 0 0 5.79 x 10-6 
4 pC3 100,000 5.79 x 10-1 5.79 x 10-6 
5 C3* 0 0 2.89 x 10-5 
6 BAX 80,000 4.63 x 10-1 5.79 x 10-6 
7 BAX* 0 0 5.79 x 10-6 
8 Mito 50,000 2.89 x 10-1 5.79 x 10-6 
9 Mito* 0 0 5.79 x 10-6 
10 Cytocm 500,000 2.89 5.79 x 10-6 
11 Cytocc 0 0 5.79 x 10-6 
12 SMACm 50,000 2.89 x 10-1 5.79 x 10-6 
13 SMACc 0 0 5.79 x 10-6 
14 PTEN 500,000 2.89 5.79 x 10-6 
15 AKT 100,000 5.79 x 10-1 5.79 x 10-6 
16 AKT* 0 0 5.79 x 10-6 
17 AKT:Cytocc 0 0 5.79 x 10-6 
18 Bcl-2 200,000 1.16 x 10-1 5.79 x 10-6 
19 Bcl-2:BAXm 0 0 5.79 x 10-6 
20 XIAP 300,000 1.74 x 10-1 5.79 x 10-6 
21 SMACc:XIAP 0 0 5.79 x 10-6 
22 BAXm 0 0 5.79 x 10-6 
23 AKT:BAX* 0 0 5.79 x 10-6 
24 PARP 100,000 5.79 x 10-1 5.79 x 10-6 
25 cPARP 0 0 5.79 x 10-6 
26 TRAIL:pC8 0 0 5.79 x 10-6 
27 C8*:pC3 0 0 5.79 x 10-6 
28 C3*:pC8 0 0 5.79 x 10-6 
29 C8*:BAX 0 0 5.79 x 10-6 
30 Mito:Cytocm 0 0 5.79 x 10-6 
31 Mito:SMACm 0 0 5.79 x 10-6 
32 Cytocc:pC3 0 0 5.79 x 10-6 
33 PTEN:AKT* 0 0 5.79 x 10-6 
34 SMACc:XIAP:AKT* 0 0 5.79 x 10-6 
35 C3*:PARP 0 0 5.79 x 10-6 
36 AKT*:XIAP 0 0 5.79 x 10-6 
37 C3*:XIAP 0 0 5.79 x 10-6 
38 C3Ub 0 0 5.79 x 10-6 
39 PTEN:XIAP 0 0 5.79 x 10-6 
40 PTENUb 0 0 5.79 x 10-6 
41 XIAP:Cytocc 0 0 5.79 x 10-6 
N/A v (volume correction) 0.07 N/A N/A 
 
  
Table S3. Reaction Rate Constants. Related to Figures 1 and 2. 
Reaction ID corresponds to the kj (forward reaction rate constant), krj (reverse reaction rate 
constant), and kcj (catalytic reaction rate constant) subscripts, j, in Table S4. 
 
Reaction 
ID (j) 
Reaction kj 
((molecules/cell)-1 s-1) 
krj 
(s-1) 
kcj 
(s-1) 
1 TRAIL + pC8  TRAIL:pC8 → C8* 10-7 10-3 1 
2 C8* + pC3  C8*:pC3 → C8* + C3* 10-6 10-3 1 
3 C3* + pC8  C3*:pC8 → C3* + C8* 3.00 x 10-8 10-3 1 
4 C8* + BAX  C8*:BAX → C8* + BAX* 10-7 10-3 1 
5 BAXm + Mito  Mito* 10-6 10-3 NA 
6 Mito* + Cytocm  Mito*:Cytocm → 
Mito* + Cytocc 
2.00 x 10-6 10-3 0.01/v 
7 Mito* + SMACm  Mito*:SMACm → 
Mito* + SMACc 
2.00 x 10-6 10-3 0.01/v 
8 Mito* → Mito 10-4 (s-1) NA NA 
9 Cytocc + pC3  Cytocc:pC3 → Cytocc 
+ C3* 
5.00 x 10-9 10-3 1 
10 PTEN   + AKT*  PTEN:AKT*  → 
PTEN + AKT 
10-8 2.00 x 10-4 1 
11 AKT* + Cytocc   AKT*:Cytocc 10-9 10-3 NA 
12 Bcl-2 + BAXm  Bcl-2:BAXm 10-6 10-3 NA 
13 SMACc + XIAP  SMACc:XIAP 3.50 x 10-6 10-3 NA 
14 AKT  AKT* 10-3 (s-1) 10-6 NA 
15 AKT* + BAX*  AKT*:BAX* 10-6 10-3 NA 
16 UNUSED NA NA NA 
17 SMACc + XIAP + AKT*  
SMACc:XIAP:AKT* → SMACc:XIAP + 
AKT 
3.50 x 10-6 
((molecules/cell)-2 s-1) 
10-3 1 
18 AKT* + XIAP  AKT*:XIAP → AKT + 
XIAP 
10-9 10-3 1 
19 C3* + XIAP  C3*:XIAP → C3Ub + 
XIAP 
7.00 x 10-5 1.67 x 10-5 1.67 x 10-4 
20 PTEN + XIAP  PTEN:XIAP → 
PTENUb + XIAP 
10-8 1.67 x 10-3 1.67 x 10-2 
21 BAX*  BAXm 0.01 (s-1) 0.01/v NA 
22 C3* + PARP  C3*:PARP → C3* + 
cPARP 
10-7 10-3 1 
23 XIAP + Cytocc  XIAP:Cytocc 10-3 10-3 NA 
 
  
Table S4. Ordinary Differential Equations (ODEs). Related to Figures 1 and 2. 
Protein ID corresponds to the xpi (protein concentration differential), xi (protein concentration), si 
(synthesis rate constant), and ri (degradation rate constant) subscripts, i. Subscripts, j, for kj 
(forward reaction rate constant), krj (reverse reaction rate constant), and kcj (catalytic reaction 
rate constant) are based on the Reaction ID shown in Table S3. 
Protein 
ID (i) 
Protein Species Ordinary Differential Equation 
1 TRAIL xp1 = -k1x1x2 +kr1x26 +s1 -r1x1 
2 pC8 xp2 = -k1x1x2 +kr1x26 -k3x5x2 +kr3x28 +s2 -r2x2 
3 C8* xp3 = +kc1x26 -k2x3x4 +kr2x27 +kc2x27 +kc3x28 -k4x3x6 +kr4x29 +kc4x29 -r3x3 
4 pC3 xp4 = -k2x3x4 +kr2x27 -k9x11x4 +kr9x32 +s4 -r4x4 
5 C3* xp5 = +kc2x27 -k3x5x2 +kr3x28 +kc3x28 +kc9x32 -k19x5x20 +kr19x37 -k22x5x24 
+kr22x35 +kc22x35 -r5x5 
6 BAX xp6 = -k4x3x6 +kr4x29 +s6 -r6x6 
7 BAX* xp7 = +kc4x29 -k15x16x7 +kr15x23 -k21x7 +kr21x22 -r7x7 
8 Mito xp8 = -(1/v)2k5x22x8 +kr5x9 +k8x9 +s8 -r8x8 
9 Mito* xp9 = +(1/v)2k5x22x8 -kr5x9 -(1/v)2k6x9x10 +kr6x30 +kc6x30 -(1/v)2k7x9x12 
+kr7x31 +kc6x31 -k8x9 
10 Cytocm xp10 = -(1/v)2k6x9x10 +kr6x30 +s10 -r10x10 
11 Cytocc xp11 = +kc6x30 -k9x11x4 +kr9x32 +kc9x32 -k11x16x11 +kr11x17 -k23x20x11 
+kr23x41 -r11x11 
12 SMACm xp12 = -(1/v)2k7x9x12 +kr7x31 +s12 -r12x12 
13 SMACc xp13 = +kc7x31 -k13x13x20 +kr13x21 -k17x13x20x16 +kr17x34 -r13x13 
14 PTEN xp14 = -k10x14x16 +kr10x33 +kc10x33 -k20x14x20 +kr20x39 +s14 -r14x14 
15 AKT xp15 = +kc10x33 -k14x15 +kr14x16 +kc17x34 +k18x36 +s15 -r15x15 
16 AKT* xp16 = -k10x14x16 +kr10x33 -k11x16x11 +kr11x17 +k14x15 -kr14x16 -k15x16x7 
+kr15x23 -k17x13x20x16 +kr17x34 -k18x20x16 +kr18x36 -r16x16 
17 AKT:Cytocc xp17 = +k11x16x11 -kr11x17 -r17x17 
18 Bcl-2 xp18 = -(1/v)2k12x18x22 +kr12x19 +s18 -r18x18 
19 Bcl-2:BAXm xp19 = +(1/v)2k12x18x22 -kr12x19 -r19x19 
20 XIAP xp20 = -k13x13x20 +kr13x21 -k17x13x20x16 +kr17x34 -k18x16x20 +kr18x36 
+kc18x36 -k19x5x20 +kr19x37 +kc19x37 -k20x14x20 +kr20x39 +kc20x39 -k23x20x11 
+kr23x41 +s20 -r20x20(1/(x16+1)) 
21 SMAC:XIAP xp21 = +k13x13x20 -kr13x21 +kc17x34 -r21x21 
22 BAXm xp22 = -(1/v)2k5x22x8 +kr5x9 -(1/v)2k12x18x22 +kr12x19 +k21x7 -kr21x22 -r22x22 
23 AKT:BAX* xp23 = +k15x16x7 -kr15x23 -r23x23 
24 PARP xp24 = -k22x5x24 +kr22x35 +s24 -r24x24 
25 cPARP xp25 = +kc22x35 -r25x25 
26 TRAIL:pC8 xp26 = +k1x1x2 -kr1x26 -kc1x26 -r26x26 
27 C8*:pC3 xp27 = +k2x3x4 -kr2x27 -kc2x27 -r27x27 
28 C3*:pC8 xp28 = +k3x5x2 -kr3x28 -kc3x28 -r28x28 
29 C8*:BAX xp29 = +k4x3x6 -kr4x29 -kc4x29 -r29x29 
30 Mito:Cytocm xp30 = +(1/v)2k6x9x10 -kr6x30 -kc6x30 -r30x30 
31 Mito:SMACm xp31 = +(1/v)2k7x9x12 -kr7x31 -kc6x31 -r31x31 
32 Cytocc:pC3 xp32 = +k9x11x4 -kr9x32 -kc9x32 -r32x32 
33 PTEN:AKT* xp33 = +k10x14x16 -kr10x33 -kc10x33 -r33x33 
34 SMACc:XIAP:AKT* xp34 = +k17x13x20x16 -kr17x34 -kc17x34 -r34x34 
35 C3*:PARP xp35 = +k22x5x24 -kr22x35 -kc22x35 -r35x35 
36 AKT*:XIAP xp36 = +k18x16x20 -kr18x36 -kc18x36 -r36x36 
37 C3*:XIAP xp37 = +k19x5x20 -kr19x37 -kc19x37 -r37x37 
38 C3Ub xp38 = +kc19x37 -r38x38 
39 PTEN:XIAP xp39 = +k20x14x20 -kr20x39 -kc20x39 -r39x39 
40 PTENUb xp40 = +kc20x39 -r40x40 
41 XIAP:Cytocc xp41 = +k23x20x11 -kr23x41 -r41x41 
 
  
Transparent Methods 
Contact for Reagent and Resource Sharing 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Matthew Anderson (m.w.anderson@exeter.ac.uk). 
Experimental Model and Subject Details 
Cell Lines 
The HCT116 cell line (Cat. No. CCL-247, ATCC; RRID: CVCL_0291) was obtained from ATCC 
(Manassas, Virginia, USA). BAX-/- HCT116, PTEN-/- HCT116, and XIAP-/- HCT116 cell lines were 
obtained from Bert Vogelstein (John Hopkins University, Maryland, USA). All cells were stored at 
-80C and subsequently grown in high-glucose DMEM medium (Cat. No. D5796, Sigma) prepared 
with 10% FBS (Cat. No. 10270106, Thermo Fisher Scientific) in an incubator at 37C with 5% 
CO2. These standard growing conditions were used throughout this study prior to the addition of 
any treatments. 
Method Details 
Model Structure 
The AKT Apoptosis Model (AKTM) was constructed using MATLAB (Mathworks) and, although 
there are other numerous mathematical models of apoptosis present in the literature to draw from 
(Bentele et al., 2004; Bertaux et al., 2017; Bialik et al., 2010; Lavrik, 2010; Schleich and Lavrik, 
2013), ours is based on the Extrinsic Apoptosis Reaction Model (EARM) series (Albeck et al., 
2008; Aldridge et al., 2011; Chen et al., 2007; Cui et al., 2008; Howells et al., 2011; Spencer et 
al., 2009) with Ordinary Differential Equations (ODEs) describing temporal variation in protein 
concentrations. This was primarily due to some of these EARM models having focused on 
HCT116 cells. With the exception of parameters relating to AKT, PTEN and their intermediaries, 
all of which were fitted to preliminary experimental data for this study, all other rate constants and 
initial conditions were parameterized according to values for HCT116 cells already obtained in 
Aldridge et al. (2011).  
Certain simplifications were applied in its construction, including the omission of caspase-8 
activation of BID, the formation of the apoptosome, and the involvement of caspase-6 in the 
positive feedback loop of the caspase cascade. In doing so, the fundamental mechanisms 
involved in the system have been conserved (see Figures 1A and 1B for comparison). 
Table S1 lists the protein species used in the AKTM, Table S2 lists the protein-specific rate 
constants and initial conditions, and Table S3 lists the reaction-specific rate constants. 
The simple rate equation, 𝑟 = 𝑘[𝐴]𝑥[𝐵]𝑦 is used for bimolecular reactions, where [𝐴] and [𝐵] are 
the concentrations of protein species A and B, respectively, and 𝑥 and 𝑦 are their partial orders 
of reaction. Since each reaction is modelled as an elementary one, these partial orders are equal 
to the stochiometric coefficients of each reactant so that in the case of bimolecular reactions, the 
reaction order is always equal to two. Bimolecular reactions such as that between TRAIL and 
procaspase-8 (pC8) are defined as shown in Equation 1 
𝑇𝑅𝐴𝐼𝐿 +  𝑝𝐶8      (𝑘𝑟𝑒𝑣)(𝑘𝑓𝑜𝑟)      𝑇𝑅𝐴𝐼𝐿: 𝑝𝐶8      →(𝑘𝑐𝑎𝑡)      𝐶8
∗ (Equation 1) 
where the reaction between TRAIL and pC8 progresses according to a forward reaction rate 
constant, 𝑘𝑓𝑜𝑟, forming a protein-protein intermediary, TRAIL:pC8. This may then either dissociate 
back into the reactants according to a reverse reaction rate constant, 𝑘𝑟𝑒𝑣, or form the products 
through a catalytic reaction rate constant, 𝑘𝑐𝑎𝑡. These reactions are modelled in terms of protein 
concentration changes with respect to time, 𝑑[𝑝𝐶8] ⁄ 𝑑𝑡. Each ODE is constructed as shown in 
Equation 2  
𝑑[𝑝𝐶8]
𝑑𝑡
= −[𝑇𝑅𝐴𝐼𝐿][𝑝𝐶8]𝑘𝑓𝑜𝑟 + [𝑇𝑅𝐴𝐼𝐿: 𝑝𝐶8]𝑘𝑟𝑒𝑣 + 𝑘𝑠𝑦𝑛 − [𝑝𝐶8]𝑘𝑑𝑒𝑔  (Equation 2) 
where 𝑘𝑠𝑦𝑛 and 𝑘𝑑𝑒𝑔  represent the synthesis and degradation rate constants for pC8, respectively. 
Additional terms following the same format are included if the focal protein species is involved in 
multiple reactions. All of the ODEs used in this model are detailed in Table S4. 
Maintaining consistency with previous EARMs—EARM v1.0 (Albeck et al, 2008) and v1.4 
(Aldridge et al., 2011) in particular—this study has modelled the apoptotic system as having 
separate cytosolic and mitochondrial compartments, the latter being approximately 7% of the 
former in volume (Posakony et al., 1977). Mitochondrial protein concentrations were, therefore, 
adjusted according to a scale factor of 1 𝑣⁄  to reflect this in rate equations, where 𝑣 = 0.07. 
However, these previous studies had not accounted for bimolecular mitochondrial reactions, 
where a scale factor of (
1
𝑣
)
2
 is required to scale the concentrations of both protein species involved 
in the reaction, as in this study. 
Model Parameters 
Basal protein concentrations for the simulated HeLa cells in EARM v1.0 (Albeck et al., 2008) were 
originally extracted from the literature, where available (Eissing, 2004; Rehm et al., 2006; 
Waterhouse et al., 2001). For unknown protein concentrations, these parameters were fitted to 
data within an observed generalized range of approximately 1–1,000 nM (Berg, 1985). EARM 
v1.4 (Aldridge et al., 2011), however, modelled the HCT116 cell line (as in this study) and found 
the basal concentrations of key proteins through quantitative immunoblotting. In this study, we 
have extracted all of the applicable parameters from EARM v1.4 and fitted the remaining 
parameters sequentially through trial-and-error to preliminary data obtained for the wild-type 
HCT116 cell line (as in Figure 4C), keeping these within the 1–1,000 nM observed generalized 
range. 
Protein synthesis rates (𝑘𝑠𝑦𝑛) were excluded from the original EARM v1.0 due to the use of 
cycloheximide (CHX), a eukaryotic protein synthesis inhibitor. However, it was found that CHX 
used at 2.5 μg/ml in previous studies did not completely inhibit synthesis, but instead reduced it 
by around 85% (Aldridge et al., 2011; Ceccarini and Eagle, 1976). Synthesis rates vary between 
proteins and are only used for those present in the system before any reactions take place (i.e. 
reactants; excluding reaction intermediaries and products) (Table S2). Degradation rates (𝑘𝑑𝑒𝑔) 
were also excluded from EARM v1.0 as they were assumed to be negligible when compared to 
other reaction rates. We—along with other later models (Aldridge et al., 2011; Spencer et al., 
2009)—assumed a half-life of 24 hours with a rate of 5.79 x 10-6 s-1, with the exceptions of active 
caspase-3 (2.89 x 10-5 s-1), the active mitochondrial pore (10-4 s-1), and ubiquitinated caspase-3 
(0 s-1). Active caspase-3 was observed as highly unstable in XIAP-/- HCT116 cells (Aldridge et al., 
2011), so the five-fold increase in degradation rate was necessary to account for this. Similarly, 
the BAX multimeric complexes forming the active mitochondrial pores were set to degrade at a 
much higher rate in order to fit experimental data. Ubiquitinated caspase-3, however, is assumed 
to be catalytically inactive, thereby acting as a caspase-3 sink in itself with no degradation rate 
required for the purposes of the model. The synthesis and degradation rates used in our model 
are listed in Table S2. 
Reaction rate constants—listed in Table S3—are based on the diffusion-limited bimolecular 
reaction rate constants in Albeck et al. (2008) and Aldridge et al. (2011), and any instances where 
two reactions were simplified and combined into one involved implementing the slower rate 
constant in the model. 
The following model simplifications were performed in the AKTM. For cases where additional 
reactions not present in previous EARM models were required, default values were initially 
applied, followed by sequential trial-and-error fitting to data for the wild-type cell line (defaults: 
𝑘𝑓𝑜𝑟 = 10
-6 (molecules/cell)-1 s-1; 𝑘rev = 10
-3 s-1; 𝑘cat = 1 s
-1). 
1) AKTM reaction: TRAIL + pC8    TRAIL:pC8  →  C8* 
Constituent reactions (EARM v1.4): 
TRAIL + Receptor    TRAIL:Receptor  →  DISC 
DISC + pC8    DISC:pC8  →  DISC + C8* 
2) AKTM reaction: C3* + pC8    C3*:pC8  →  C3* + C8* 
Constituent reactions (EARM v1.4): 
C3* + pC6    C3*:pC6  →  C3* + C6* 
C6* + pC8    C6*:pC8  →  C6* + C8* 
3) AKTM reaction: C8* + BAX    C8*:BAX  →  C8* + BAX* 
Constituent reactions (EARM v1.4): 
C8* + BID    C8*:BID  →  C8* + tBID 
tBID + BAX    tBID:BAX  →  tBID + BAX* 
4) AKTM reaction: BAXm + Mito    Mito* 
Constituent reactions (EARM v1.4): 
BAXm + BAXm    BAX2m 
BAX2m + BAX2m    BAX4m 
BAX4m + Mito    BAX4m:Mito  →  Mito* 
5) AKTM reaction: Mito* + Cytocm    Mito*:Cytocm  →  Mito* + Cytocc 
Constituent reactions (EARM v1.4): 
Mito* + Cytocm    Mito*:Cytocm  →  Mito* + Cytocr 
Cytocr    Cytocc 
6) AKTM reaction: Mito* + SMACm    Mito*:SMACm  →  Mito* + SMACc  
Constituent reactions (EARM v1.4): 
Mito* + SMACm    Mito*:SMACm  →  Mito* + SMACr 
SMACr    SMACc 
7) AKTM reaction: Cytocc + pC3    Cytocc:pC3  →  Cytocc + C3* 
Constituent reactions (EARM v1.4): 
Cytocc + APAF1    Cytocc:APAF1  →  Cytocc + APAF1* 
APAF1* + C9    Apoptosome 
Apoptosome + pC3    Apoptosome:pC3  →  Apoptosome + C3* 
8) AKTM reaction: XIAP + Cytocc    XIAP:Cytocc 
Constituent reactions (EARM v1.4): 
Cytocc + APAF1    Cytocc:APAF1  →  Cytocc + APAF1* 
APAF1* + C9    Apoptosome 
Apoptosome + XIAP    Apoptosome:XIAP 
9) AKTM reaction: PTEN + AKT*    PTEN:AKT*  →  PTEN + AKT 
Constituent biochemical reactions: 
PTEN + PIP3    PTEN:PIP3  →  PTEN  +  PIP2 
PIP3 + AKT    PIP3:AKT  →  PIP2 + AKT* 
10) AKTM reaction: AKT* + Cytocc    AKT*:Cytocc 
Constituent biochemical reactions: 
Cytocc + APAF1    Cytocc:APAF1  →  Cytocc + APAF1* 
APAF1* + C9    Apoptosome 
C9 + AKT*    C9:AKT* 
Eigenanalysis 
Eigenvalues were calculated and used to quantify how sensitive particular protein species are to 
small changes in the system. The more positive an eigenvalue’s real part—as opposed to the 
complex number’s imaginary part—the more unstable the system is in the direction of the 
corresponding eigenvector, indicating which protein species will change in concentration the most 
due to the instability.  For example, the index of the smallest absolute value within the eigenvector 
singles out the protein that will have changed the least at the point of instability, whereas the index 
of the largest absolute value refers to the protein that is the most sensitive and hence will have 
changed in concentration the most. This is useful information to have during the modelling 
process since it can help to simplify the system and thereby focus the model. Moreover, an 
understanding of which proteins are most sensitive to perturbations allows for more effective 
targeting of subsequent experimental work and the development of therapeutic drugs. However, 
eigenvalues are only justified when variables—in this case, protein concentrations—are slow 
compared to the magnitude of the eigenvalues because they are representations of the 
instantaneous dynamics occurring around steady states (Fenichel, 1979; Jones, 1995). When the 
system is near steady state, the time dependence can be thought of as a perturbation and the 
magnitude of the eigenvalues indicate the sensitivity to this perturbation. The eigenvectors then 
indicate how various species are expected to react to this perturbation. The largest relative 
component of an eigenvalue indicates the protein that is most sensitive, because its variation is 
expected to be the largest. In the AKTM, identification of the most sensitive proteins was less 
reliable from 4-6 hours, because the dynamics became relatively fast during this time; a factor 
that is considered in our analyses. 
To calculate eigenvalues, the model simulation was run and the Jacobian matrix calculated at 
each sampled solution value as a function of time. Mathematically, if  𝑥  is the system’s set of 
protein concentrations, then  𝑑𝑥 𝑑𝑡⁄ = 𝑓(𝑥) , where  𝑓(𝑥)  is the collection of ODEs describing its 
dynamics. The Jacobian matrix was then approximated from a small change function ( 𝜀 ) applied 
to  𝑓(𝑥) , such that the  𝑘𝑡ℎ  column of the Jacobian matrix as 𝜀 → 0 is approximately equivalent 
to  (𝑓(𝑥 + (𝜀 × 𝑣𝑘)) − 𝑓(𝑥)) 𝜀⁄  , where  𝜀  is a small perturbation and  𝑣𝑘  represents the  𝑘𝑡ℎ  unit 
vector. The eigenvalues of the Jacobian matrix were then computed at each time point and these 
amassed into a larger matrix of dimensions, 𝑛 × 𝑡 , where  𝑛  is the number of protein species and  
𝑡  is the number of time points. In addition to the eigenvalues, the eigenvectors were also stored 
in an even larger 𝑛 × 𝑛 × 𝑡 matrix. From these two matrices, any protein species represented by 
positive eigenvalues could be determined, and this information used to infer the protein species 
most sensitive to perturbations. 
Cell Death Assays 
In preparation for live-cell microscopy, cells were grown to 70% confluency in 35 mm glass-
bottomed dishes (Cat. No. P35G-0-14-C, MatTek Corp.). An Olympus IX-71 inverted microscope 
(60× Uplan Fluorite objective; 0.65-1.25 NA, oil) was used for imaging, encased by an incubator 
calibrated to 37C and 5% CO2. Three treatments were applied to cells in high-glucose DMEM 
medium: control (DMEM only); 2.5 μg/ml Cycloheximide (CHX) (Cat. No. C7698, Sigma); and 2.5 
μg/ml CHX + 50 ng/ml TNF-related apoptosis-inducing ligand (TRAIL) (SuperKillerTRAIL: Cat. 
No. ALX-201-115-C010, Enzo Life Sciences). CHX was included to inhibit new protein synthesis 
and focus on protein interaction dynamics. A concentration of 2.5 μg/ml has been shown to reduce 
synthesis rates to 15% of their normal values (Aldridge et al., 2011; Ceccarini and Eagle, 1976), 
a change that is reflected in the synthesis rates of the model. All treatments were applied to the 
following four cell lines immediately prior to imaging: HCT116; BAX-/- HCT116; PTEN-/- HCT116; 
and XIAP-/- HCT116. Images were taken with a CoolSNAP HQ CCD camera (Photometrics) at 
5-minute intervals for 16 hours and videos created from these using MetaMorph software 
(Molecular Devices). Further cell death assays were carried out in wild-type HCT116 cells 
transiently expressing IRES-GFP, PTEN-IRES-GFP or catalytically inactive C124S PTEN-IRES-
GFP (provided by Prof. Kate Nobes, Bristol). For these assays, 75,000-100,000 HCT116 cells 
were reverse transfected in 96-well plates with the above constructs, and 48 hours later, treated 
with 2.5 µg/ml CHX in the absence or presence of 50ng/ml TRAIL for 2 or 6 hours. Cells were 
then lysed and assayed for caspase activity using the EnzChek™ Caspase-3 Assay Kit Z-DEVD-
AMC substrate (Cat. No. E13183, Thermo Fisher) according to manufacturer’s instructions. Cell 
lysates were transferred to Costar 96-well black clear bottom plates (Cat. No. 10530753, Thermo 
Fisher), and fluorescence was measured in Glomax plate reader (Promega; 365nm excitation, 
410–465 emission). 
  
Immunoblotting 
Cells were grown to 80% confluency in 12-well plates (Cat. No. 3513, Corning) and rinsed with 2 
ml ice-cold Phosphate Buffered Saline (PBS) (Cat. No. BR0014G, Thermo Fisher Scientific). The 
cells in each well were lysed with 100 μl RIPA buffer (Cat. No. 89900, Thermo Fisher Scientific) 
and lysates kept on ice with regular agitation for 15 minutes before being centrifuged at 15,294 g 
for 5 minutes. Supernatants were finally collected and either used directly for protein quantification 
or stored at -80°C. 
Lysate protein quantification was achieved using the standard test tube protocol of the Pierce™ 
Bicinchoninic Acid (BCA) Protein Assay Kit (Cat. No. 23225, Thermo Fisher Scientific). In brief, 
the assay was performed by calculating protein concentrations from measured absorbances at 
562 nm of BCA/copper complex-reacted protein lysate samples against those of a set of 
pre-diluted bovine serum albumin (BSA) protein assay standards.  
Protein separation was achieved by Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE). 5-20 μl of sample was added to each well so that 15 μg of protein was present in 
each. Samples were measured against 4 μl Precision Plus Protein™ All Blue Prestained Protein 
Standard (Cat. No. 1610373, Bio-Rad). Proteins were transferred to nitrocellulose membranes 
(Cat. No. 11998905, Fisher Scientific UK) using a Trans-Blot® Turbo™ Transfer Kit (Cat. No. 
1704270, Bio-Rad). These were blocked either using 5% (w/v) skimmed milk powder or with 5 % 
BSA in Tris-buffered saline containing 0.1% Triton X-100 (according to the manufacturer’s 
recommendations) and probed with primary antibodies followed by horseradish peroxidase 
(HRP)-tagged secondary antibodies. Proteins were imaged by enhanced chemiluminescence. 
Antibodies used are listed in the Key Resources Table. 
qRT-PCR 
Target cells were grown to confluency in 6-well plates and rinsed with 2 ml ice-cold PBS. RNA 
was extracted using the RNeasy Mini Kit (Cat. No. 74104, Qiagen), following the manufacturer’s 
instructions. Total RNA was converted into cDNA, following the Life Technologies RNA-to-cDNA 
protocol and amplified by real-time polymerase chain reaction; 37oC for 60 minutes and 95oC for 
5 minutes.  
For qRT-PCR, each condition had three distinct triplicates, and each of these run in triplicate to 
assess pipetting accuracy between samples. Per sample, 2 μl cDNA was added to 0.5 μl of the 
forward and reverse primers at 5 μM each, 5 μl SYBR-Green (Cat. No. 4309155, Life 
Technologies) and 2 μl H2O, to one well of a 96-well plate. GAPDH was used as a protein control 
for every plate. 
Immunoprecipitation 
Cells plated on 10 cm dishes were washed with ice-cold PBS and lysed in IP lysis buffer (50 mM 
Tris HCl; pH 7.5, 150 mM NaCl, 0.5% Triton X-100 and proteinase inhibitor tablet (Cat. No. 
11836153001, Sigma)). Samples were incubated on ice for 10 minutes then centrifuged at 13,000 
xg for 15 minutes at 4°C and the supernatants collected as soluble protein fractions. 200 µg 
protein was incubated for 3 hours at 4°C with 3 µg of antibody (anti-BAX, anti-PTEN or anti-FLAG 
as a control (Cat. No. A00187, Genscript)). Samples were then incubated with protein G 
sepharose beads (Cat. No. ab193259, Abcam) for precipitation for 2 hours at 4°C. Beads were 
washed four times with IP lysis buffer containing 0.1% Triton X-100 and results were analysed by 
immunoblotting, as described above. 
siRNA of PTEN in the WT line 
Knockdown (KD) experiments were performed using 20 μM siRNA construct to target GL2 
(control, Eurofins Genomic: CGUACGCGGAAUACUUCGAUU(dTdT)) or PTEN (Mission 
esiRNA; Cat. No. EHU106441, Sigma) using Lipofectamine 2000 (Cat. No. 11668019, Thermo 
Fisher Scientific) as per the manufacturers’ instructions. Cells were left for 48 hours before being 
lysed as above. 
AKT Inhibition Assays 
The IncuCyte® imaging system was used to conduct large live-cell experiments with numerous 
treatments. Through comparisons with previously performed cell death assays, this system was 
found to be the optimum means of imaging dying cells since any background cell death inherent 
to confocal imaging and human interference was minimized by the incorporation of an imaging 
system within the incubator. Target cells were first plated on 96-well plates and grown to 70% 
confluency. Treatments were applied to wells immediately prior to imaging using a multichannel 
pipette. Six treatments were applied to all four HCT116 cell lines in fresh high-glucose DMEM: 
control (DMEM only); 27.6 μg/ml AKT1/2 Kinase Inhibitor (AKTi) (Cat. No. A6730, Sigma); 2.5 μ 
g/ml CHX; 2.5 μ g/ml CHX + 27.6 μg/ml AKTi; 50 ng/ml TRAIL + 2.5 μg/ml CHX; and 50 ng/ml 
TRAIL + 2.5 μ g/ml CHX + 27.6 μg/ml AKTi. Manufacturer specifications (Sigma) for AKTi showed 
an IC50 of 58 nM, 210 nM, and 2.12 mM for AKT1, AKT2, and AKT3, respectively, and a “high 
concentration” of 50 μM (27.6 μg/ml). 250 nM IncuCyte® Cytotox Red Reagent (Essen 
BioScience) was used to detect dead cells in the red channel. This reagent fluoresces upon 
binding to DNA once plasma membrane integrity has been compromised in dying cells. Two 
images were taken at each well at 30-minute intervals in both the phase contrast and red 
channels. IncuCyte ZOOM® software (Essen BioScience) was used to process and create videos 
from these images. 
Quantification and Statistical Analysis 
All statistical tests were performed in R (https://www.r-project.org/) using the RStudio user 
interface (https://www.rstudio.com/). Three independent experiments (n = 3) were performed in 
all cases, from which means and their standard deviations (SDs) were calculated. Statistical 
significance was defined by a result giving a p-value ≤ 0.05. One-tailed t-tests were used for 
immunoblots in Figure 5, but all other statistical tests (Figures 4 and 6) were Welch two-sample 
t-tests. Detailed statistical results for all applicable figures are displayed in Table S5. 
Protein Quantification 
Immunoblot images were imported into MATLAB and normalized for background brightness. 
Pixels were then thresholded and counted, from which their mean “greyness” calculated and 
quantified values produced. Values for all mutant cell lines corresponding to a single antibody 
were then normalized relative to that of wild-type, and mutant cell line means and their SDs 
calculated from three separate experiments (n = 3). One-tailed t-tests were then used to test 
whether the means for each antibody-specific mutant cell line differed significantly from one (the 
normalized value for wild-type). In cases where no protein was detected in a cell line—for 
example, when blotting for BAX in the BAX-/- line—statistical testing found a highly significant 
difference between its mean of zero (with SD = 0) and that of the wild-type cell line (each repeat 
normalized to 1, therefore also with SD = 0). In these cases, as a consequence of testing zero 
against one, t-values were negative infinity (-Inf), degrees of freedom (df) were 2, and p-values < 
2.2 x 10-16.  
AKT Inhibition Assays 
Videos produced in AKT inhibition experiments were analyzed using custom MATLAB code 
developed using the Miji framework (Daniel Sage, Biomedical Image Group) to incorporate Fiji 
(Schindelin et al., 2012)—an image analysis suite of ImageJ (https://imagej.nih.gov/ij/)—into the 
MATLAB environment. This enabled Fiji tools to be utilized through MATLAB, thereby allowing 
for automated processing and cell counting of numerous large video files. With the exception of 
an adjustment in thresholding, the process for counting live and dead cells was identical, both 
involving the application of a bandpass filter followed by finding the local maxima based on the 
filters used. Each experiment was performed in triplicate (n = 3), from which means and their SDs 
were calculated at each 30-minute interval. Data were extracted from these experiments from the 
4-, 6- and 8-hour time points, and Welch two-sample t-tests performed both between different cell 
lines within each treatment and between different treatments for each cell line.  
Data and Software Availability 
Raw data for the cell death assays (Figure 4), Western blot quantification (Figure 5), and AKT 
inhibition experiments (Figure 6) are available online via a Mendeley Data repository with DOI 
links as follows: 
Cell death assays (Figure 4): http://dx.doi.org/10.17632/hvwswmgg7p.1 
Western blot quantification (Figure 5): http://dx.doi.org/10.17632/x8v9937psj.1 
AKT inhibition experiments (Figure 6): http://dx.doi.org/10.17632/74pf4wwdd4.1 
Key Resources Table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Anti-AKT (pan) (mouse 
monoclonal) 
Cell Signaling Cat. No. 2920 
Anti-p-AKT S473 (rabbit 
monoclonal) 
Cell Signaling Cat. No. 4060 
Anti-BAX (rabbit polyclonal) Cell Signaling Cat. No. 2772 
Anti-PTEN (rabbit 
monoclonal) 
Cell Signaling Cat. No. 9559 
Anti-XIAP (rabbit 
monoclonal) 
Cell Signaling Cat. No. 14334 
Anti-α-Tubulin (mouse 
monoclonal) 
Sigma Cat. No. T5168 
Anti-Mouse HRP-
conjugated secondary 
antibody (goat polyclonal) 
SignalChem Cat. No. G32-62G-1000 
Anti-Rabbit HRP-conjugated 
secondary antibody (goat 
polyclonal) 
SignalChem Cat. No. G33-62G-1000 
Anti-GAPDH (mouse 
monoclonal) 
Sigma Cat. No. G8796 
Anti-FLAG (mouse 
monoclonal) 
Genscript Cat No. A00187 
Chemicals, Peptides, and Recombinant Proteins 
RIPA buffer Thermo Fisher Scientific Cat. No. 89900 
Sodium Dodecyl Sulfate 
(SDS) 
Fisher Scientific UK Cat. No. S520053 
30% acrylamide / 0.8% 
(w/v) bisacrylamide 
Severn Biotech Cat. No. 20-2100-10 
Ammonium persulfate 
(APS) 
Bio-Rad Cat. No. 1610700 
Tetramethylethylenediamine 
(TEMED) 
Bio-Rad Cat. No. 1610800 
Precision Plus Protein All 
Blue Prestained Protein 
Standards 
Bio-Rad Cat. No. 1610373 
ECL Western Blotting 
Detection Reagents 
Sigma Cat. No. GERPN2209 
SuperKillerTRAIL (human) Enzo Life Sciences Cat. No. ALX-201-115-C010 
Cycloheximide Sigma Cat. No. C7698 
IncuCyte Cytotox Red 
Reagent 
Essen BioScience Cat. No. 4632 
AKT1/2 Kinase Inhibitor Sigma Cat. No. A6730 
SYBR-Green  Life Technologies Cat No. 4309155 
Lipofectamine 2000 Thermo Fisher Scientific Cat No. 11668019 
Proteinase inhibitor tablet Sigma Cat No. 11836153001 
Protein G Sepharose beads Abcam Cat No. ab193259 
Critical Commercial Assays 
Pierce BCA Protein Assay 
Kit 
Thermo Fisher Scientific Cat. No. 23225 
Trans-Blot Turbo Transfer 
Kit 
Bio-Rad Cat. No. 1704270 
RNeasy Mini Kit   Qiagen Cat No. 74104 
Deposited Data 
Cell death assays raw data Mendeley Data http://dx.doi.org/10.17632/hvwswmgg7p.1 
 
Densitometry data Mendeley Data http://dx.doi.org/10.17632/x8v9937psj.1 
 
AKT inhibition assays raw 
data 
Mendeley Data http://dx.doi.org/10.17632/74pf4wwdd4.1 
 
Experimental Models: Cell Lines 
HCT116 (human colorectal 
carcinoma) 
ATCC Cat. No. CCL-247; RRID: CVCL_0291 
HCT116 BAX-/- Zhang et al. (2000) N/A 
HCT116 PTEN-/- Lee et al. (2004) N/A 
HCT116 XIAP-/- Cummins et al. (2004) N/A 
Software and Algorithms 
MATLAB Mathworks N/A 
R N/A https://www.r-project.org/ 
RStudio N/A https://www.rstudio.com/ 
ImageJ N/A https://imagej.nih.gov/ij/ 
Fiji Schindelin et al. (2012) https://fiji.sc/ 
Miji Daniel Sage, EPFL, 
Switzerland  
https://imagej.net/Miji/ 
IncuCyte ZOOM Essen BioScience N/A 
MetaMorph Molecular Devices N/A 
Excel Microsoft N/A 
AKT Apoptosis Model This study N/A 
Cell death quantification 
algorithms 
This study N/A 
Protein quantification 
algorithms 
This study N/A 
Other 
Dulbecco's Modified Eagle's 
Medium (DMEM) 
Sigma Cat. No. D5796 
Fetal Bovine Serum (FBS) Thermo Fisher Scientific Cat. No. 10270106 
Phosphate Buffered Saline 
(PBS) 
Thermo Fisher Scientific Cat. No. BR0014G 
0.45 μm nitrocellulose 
transfer membranes 
Fisher Scientific UK Cat. No. 11998905 
Hyperfilm Sigma Cat. No. GE28-9068-36 
Primers for qRT-PCR 
Gene Forward Primer Reverse Primer 
BAX 5’-CCGCCGTGGACACAGAC-3′ 5′-CAGAAAACATGTCAGCTGCCA-3′ 
GAPDH 5’-TTGAGGTCAATGAAGGGGTC-3’ 5’-GAAGGTGAAGGTCGGAGTCA-3’ 
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